Research on how cancer spreads through the body. Covers metastasis monitoring, bone metastasis, and nanoparticle treatments.
Researchers found that a quarter of cancer patients want to know their life expectancy, while almost half want to know about their functional prognosis. The study suggests that doctors should consider various options for informing patients about their future to cater to individual needs.
In the ARROS-1 trial, 48% of patients achieved partial responses to NVL-520, with responses seen across all dose levels and in heavily pre-treated patients. The treatment also showed promise for brain metastases, with three out of three patients experiencing measurable response or no emergence of new metastases.
Advanced nanoparticles carrying a bacterially derived compound target the STING pathway, disrupting blood vessels and stimulating an immune response. This approach suppresses tumor growth and metastasis in several types of cancers.
Researchers at Baylor College of Medicine found that initiating bone repair triggers bone metastasis, with cancer cells 'riding' NG2-positive stem cells to tumor sites. This finding offers new directions for preventing tumor recurrence and controlling bone metastasis.
Researchers have identified a messenger substance called ANGPLT4 that promotes tumor growth locally but suppresses metastasis when released into the bloodstream. This discovery sheds light on why metastases often appear after the original tumor has been surgically removed.
A new study finds that combining radiation with hormone therapy can improve outcomes for patients with oligometastatic prostate cancer. The trial showed that patients who received both treatments experienced longer progression-free survival and better testosterone levels after treatment.
A large-scale analysis of VA medical centers found that facilities with lower yearly PSA screening rates had higher rates of metastatic prostate cancer in subsequent years. The study supports the benefits of prostate cancer screening in reducing metastatic prostate cancer risk, particularly for high-risk groups like Black patients.
In a first-in-human trial, FLASH radiation treatment was found safe and effective for pain relief in patients with bone metastases. The study showed significant pain relief in 7 out of 10 patients, with minimal side effects.
A phase II trial suggests that radiation can reduce painful complications and hospitalizations, and possibly extend overall survival in patients with advanced cancers. The study found that treating asymptomatic lesions with radiation reduced skeletal-related events and extended overall survival compared to those who received no radiation.
A novel polysorbate-based formulation enhances carboplatin's therapeutic response in lymph nodes, amplifying antitumor effects and increasing drug penetration.
A study from Tokyo Medical and Dental University reveals that the TGF-β signaling molecule can induce EMT in oral cancer cells, leading to high motility and metastatic potential. KRTAP2-3 expression is associated with poorer overall survival, suggesting its role as a prognostic biomarker.
A gene signature of four specific genes (SAA1, SAA2, APOL1, and MET) predicts the risk of tumour spreading and survival in kidney cancer patients. The study identified a link between the microenvironment and immune system inhibition.
Researchers at the University of Bonn have identified a mechanism that helps dendritic cells migrate more quickly to lymph nodes. The discovery reveals that forming multiple centrosomes enables these immune cells to stay on course longer before continuing their search.
Research reveals that individuals with inflammatory breast cancer are at a higher risk of brain metastases, which can lead to improved survival rates and quality of life. The study suggests that patients with triple-negative breast cancer face an even higher risk, emphasizing the need for earlier detection and more aggressive treatment.
Researchers found that certain fungal species in tumors are linked to inflammation and reduced cell-to-cell adhesion, features associated with late-stage cancer spread. High levels of these fungi may serve as biomarkers for metastasis risk and lead to more effective treatment choices.
Scientists have identified two new epigenetic biomarkers that can predict the development of aggressive prostate cancer, enabling clinicians to develop more personalized treatment plans. The study used comprehensive molecular analysis of 185 biopsies from men with prostate cancer diagnosed between 1990 and 2000.
Scientists have identified a protein that regulates cancer cell spread and normal tissue cell shedding, potentially leading to new treatments. The research suggests that metastasis is not an abnormal process limited to cancer but a normal process used by healthy cells.
Research from UVA Cancer Center finds that an unhealthy gut microbiome can trigger changes in normal breast tissue, facilitating cancer's spread to other parts of the body. The study suggests that targeting the gut-mast cell relationship could help prevent breast cancer recurrence and metastasis.
A team from UNIGE and HUG identified a protein regulation mechanism that reduces melanoma cells' capacity to adapt and resist treatment. They found that targeting this mechanism with an enzyme inhibitor reduces therapeutic resistance in all melanoma cells.
Researchers discovered a type of triple-negative breast cancer cell that can trigger dormancy, evading therapies and allowing for efficient survival in distant organs. This finding highlights the need for more selective therapeutic strategies targeting both dividing and invasive dormant cells.
Tel Aviv University researchers discovered that skin cancer cells interact with astrocytes in the brain, promoting metastasis. By inhibiting this interaction using existing treatments, they delayed the spread of melanoma to the brain by 60-80%. This breakthrough has implications for treating advanced-stage melanoma.
The Montefiore Einstein Cancer Center has received a $10 million grant from the National Cancer Institute to study lung metastasis in breast cancer. The research aims to understand the mechanisms of tumor cells seeding tumors in the lungs, a key site for triple-negative breast cancer metastasis.
Researchers at Tohoku University have developed a novel cancer therapy combining lymphatic drug delivery with total-body irradiation, showing superior antitumor effects in early stage lymph node metastasis. The treatment enhances systemic tumor immune responses and alters the tumor microenvironment.
Breast cancer recurrence and metastatic spread remain a significant challenge, with researchers identifying a metabolic signature that can predict patient outcomes. The signature could be used to develop new therapies targeting cancer metabolism.
Researchers identified high-risk patients with stage 3A disease and microscopic lymph node metastases who would benefit from adjuvant therapy. Patients with larger metastases had poorer outcomes, while those with smaller metastases had better survival rates similar to stage 1A disease.
Researchers identified differences in PTK activity between normal and cancer kidney tissue, with Src family kinases and PI3K pathways exhibiting high activity. Ex vivo treatment of clear cell RCC with TKIs revealed that tivozanib and cabozantinib were more potent inhibitors than sunitinib or pazopanib.
Researchers at Georgia Tech have developed a new chip that can detect cancer metastasis in blood samples with high precision and scalability. The Cluster-Well chip uses microfluidic technology to isolate circulating tumor cell clusters, allowing for earlier and more targeted treatment.
Scientists have developed a smart contact lens that can capture and detect exosomes, nanometer-sized vesicles found in bodily secretions, which hold promise for cancer diagnostics. The lens was designed to bind to antibodies capturing exosomes found in tears, offering a potential platform for non-invasive cancer screening.
Researchers discovered that high levels of collagen type XII can trigger breast cancer cells to spread from the tumour to other parts of the body. The study suggests that measuring collagen XII levels in a patient's tumour biopsy could be used as an additional screening tool to identify aggressive breast cancers.
Researchers have identified key molecular differences between cancer cells that cling to initial tumors and those that spread to distant sites. The study found unique properties in cells that gain migratory ability and survival advantages, leading to the development of new treatment targets.
Researchers at Dartmouth Cancer Center developed a new approach for detecting and quantifying tumor heterogeneity in breast cancer. High levels of heterogeneity are linked to poor patient outcomes, while specific proteins regulate its extent. The study aims to utilize this approach in therapeutic decision-making.
Researchers at the Centre for Genomic Regulation have identified PDIA6 as a key protein involved in driving melanoma malignancy. The study found that PDIA6 promotes melanoma cell growth by binding to RNA molecules inside tumor cells, making it a promising therapeutic target.
A team of researchers has discovered that malignant tumors accumulate lipid delivery molecules called LDL and attract immune suppressor cells called neutrophils, leading to tumor progression. The study also shows that targeting the LOX-1/oxidized LDL axis may be a promising strategy for treating both cancer and cardiovascular disease.
A team of researchers developed a clonal barcoding approach to track live cancer cells, enabling the detection and isolation of precise clones responsible for tumor formation and early metastases. This technology has the potential to be applied to other cell-based studies, providing valuable insights into biological processes.
Scientists use a unique tool to apply mechanical forces that affect protein folding, revealing talin's interaction with tumor-suppressing protein DCL1. This discovery provides insight into the antitumor effect of DCL1 and potential new treatments for metastatic cancer.
Researchers uncovered details about the underlying biology of melanoma brain metastases, including genomics, immunology, and spatial organization. The study found that melanoma brain metastases are more chromosomally unstable than other types of metastases, with potential therapeutic targets in reduced chromosomal instability.
Researchers at Moffitt Cancer Center discovered that gains in chromosome 1q stimulate a network of competitive endogenous RNA molecules that promote melanoma metastasis. These RNA sequences act as 'ceRNAs' that sponge miRNA molecules, driving tumor growth and development.
Researchers analyzed germline variants in breast cancer patients to identify their role in metastasis development. The study found that host genetic makeup contributes to metastasis through dysregulation of gene expression, promoting the dispersion of metastatic seeds and establishing a conducive environment for their growth.
A preclinical study by Cedars-Sinai Cancer and Johns Hopkins University has discovered a novel three-step treatment that disrupts the pancreatic tumor microenvironment in laboratory mice. The treatment, which combines anti-PD-1 immunotherapy antibody, FAKi, and CXCR4, prevents cancer metastasis and bolsters the immune system.
Researchers discover G6PD's pivotal role in activating pentose phosphate pathway to counter oxidative stress, leading to increased cell death and tumor shrinkage. Ovarian cancer cells' reliance on fatty acid metabolism fuels oxidative compound production, which can be offset by G6PD inhibition.
Cancer cells with high mitochondrial RNA modifications have increased protein synthesis in mitochondria, supporting their invasive spread. A specific enzyme, NSUN3, is responsible for these modifications and serves as a biomarker for metastatic tumours.
Researchers found that suppressing an enzyme called MSRA, which fixes oxidative damage to proteins, sparks the metastatic spread of pancreatic cancer cells. The discovery suggests that similar switches may exist in other cancers and lays the groundwork for redox-based targeted therapies.
This volume of Oncotarget features groundbreaking research on various cancers, including breast, lung, colorectal, and neuroblastoma, as well as novel drug targets for bladder cancer. The studies also delve into the role of BRCA in breast and colorectal cancers.
A novel liquid biopsy test can accurately detect cancer DNA in the blood of patients with metastatic breast cancer within five hours, potentially helping oncologists determine if treatments are working. The test's diagnostic accuracy is 85%, correctly detecting cancer 83% of the time and ruling out cancer 92% of the time.
Researchers found that 'killer' T-cells used in immunotherapy can also destroy tumour lymphatic vessels, greatly reducing the risk of metastasis. This synergistic effect could increase treatment effectiveness against cancers with high lymphangiogenesis.
A novel BRAF inhibitor, C1a, has been developed to cross the blood-brain barrier and treat melanoma brain metastasis. The study found that C1a triggered robust responses in patient-derived models and outperformed approved BRAF inhibitors, achieving significant increases in survival rates.
Researchers from Japan and the US share new technologies and blood biomarkers to detect pancreatic cancer and identify high-risk individuals. The findings aim to decrease cancer mortality rates by developing attractive new methods for early diagnosis.
Researchers led by Atsuo Sasaki aim to identify mechanisms behind cell movement and energy allocation in cancer cells, with potential applications beyond cancer treatment. They will use scanning ion-conductance microscopy and machine learning technology to study the role of GTP in cellular migration.
A phase 2 trial of the experimental drug adagrasib showed a 42.9% objective response rate and median overall survival of 12.6 months in patients with KRAS-mutated non-small cell lung cancer. The treatment also achieved a 33.3% response rate in patients with stable brain metastases.
A study by Cedars-Sinai researchers confirms that counting metastatic lymph nodes is a dominant predictor of cancer death, improving staging and treatment for solid tumors. The simple process can be applied in virtually all medical settings without increased cost or complexity.
New research reveals that age-induced changes in lung fibroblasts reactivate dormant melanoma cells, promoting growth and metastasis. The study found that WNT5A signaling pathway regulates tumor cell dormancy and metastasis initiation, with increased sFRP1 secretion facilitating reactivation in the aged lung.
New research suggests vitamin D can effectively prevent ovarian cancer by restoring the body's natural defenses. The study found that vitamin D counteracts the process of peritoneal metastasis, which allows cancer cells to spread, and strengthens the barrier effect of mesothelial cells.
The ECOG-ACRIN Cancer Research Group presented promising trial results at ASCO 2022, including an 8-year survival rate in the CHAARTED prostate trial. The research also explored outcomes by tobacco use in head and neck studies, shedding light on cancer treatment effectiveness.
A meta-analysis published in The Lancet Oncology suggests that targeted radiation therapy, which spares healthy brain tissue, is equitable to whole brain radiation therapy for patients with small cell lung cancer and brain metastases. This approach may improve their care experience with fewer negative cognitive consequences.
Kaiser Permanente researchers present 10 studies on improving cancer care delivery, including strategies to reduce hospitalizations and mortality among older patients. The studies also explore the use of real-world data versus clinical trials in cancer treatment.
MD Anderson research highlights new treatments for skin cancers, including novel therapies. The institution also showcased improved goals of care programs, which demonstrated significant reductions in ICU mortality and improved patient outcomes during the COVID-19 pandemic.
Researchers at HKU have discovered a novel cellular and molecular interaction between cancer cells and tumour-associated macrophages that promote peritoneal metastasis of ovarian cancer. The study reveals that Wnt/b-catenin signalling upregulates the expression of metadherin, which communicates with macrophages through CEACAM1.
Researchers identified genetic patterns in brain metastatic prostate cancer cells, revealing potential targets for PARP inhibitor therapy. This study contributes to precision medicine by tailoring treatment to individual patient profiles.
A recent study published in Nature Communications found that healthy developing neurons promote metastatic behaviour in neuroblastoma cells. This discovery highlights the importance of understanding the unique developmental environment within which cancers of embryonic origin form.
The new ASTRO guideline provides guidance on radiation therapy for brain metastases, including evidence-based recommendations for multidisciplinary planning and delivery of advanced techniques to manage intact and resected brain tumors. The guideline aims to improve quality of life and outcomes for patients with brain metastases.